Open AccessThis article is
- freely available
The Treatment of Melioidosis
Division of Microbiology & Infectious Diseases, PathWest Laboratory Medicine WA, QEII Medical Centre, Nedlands, WA 6009, Australia
Microbiology & Immunology, School of Biomedical, Biomolecular and Chemical Sciences, Faculty of Life & Applied Sciences, University of Western Australia, Crawley, WA 6009, Australia
School of Pathology and Laboratory Medicine, Faculty of Medicine & Dentistry, University of Western Australia, Crawley, WA 6009, Australia
Received: 19 January 2010; in revised form: 29 March 2010 / Accepted: 20 April 2010 / Published: 27 April 2010
Abstract: Melioidosis is a complex bacterial infection, treatment of which combines the urgency of treating rapidly fatal Gram negative septicaemia with the need for eradication of long-term persistent disease in pulmonary, soft tissue, skeletal and other organ systems. Incremental improvements in treatment have been made as a result of multicentre collaboration across the main endemic region of Southeast Asia and northern Australia. There is an emerging consensus on the three main patterns of antimicrobial chemotherapy; initial (Phase 1) treatment, subsequent eradication (Phase 2) therapy and most recently post-exposure (Phase 0) prophylaxis. The combination of agents used, duration of therapy and need for adjunct modalities depends on the type, severity and antimicrobial susceptibility of infection. New antibiotic and adjunct therapies are at an investigational stage but on currently available data are unlikely to make a significant impact on this potentially fatal infection.
Keywords: melioidosis; treatment; antibiotics; adjunct therapy
Citations to this Article
Cite This Article
MDPI and ACS Style
Inglis, T.J. The Treatment of Melioidosis. Pharmaceuticals 2010, 3, 1296-1303.
Inglis TJ. The Treatment of Melioidosis. Pharmaceuticals. 2010; 3(5):1296-1303.
Inglis, Timothy J.J. 2010. "The Treatment of Melioidosis." Pharmaceuticals 3, no. 5: 1296-1303.